Skip to main content

Solvay to take impairment

In a Q2 trading update, Solvay revealed that an impairment review is under way and likely to lead to a non-cash impairment of about €1.5 billion. This is the result of “the deterioration in short and mid term economic performance due to Covid-19,” the company said.

How Solvay plans to GROW

Solvay has announced its new 'GROW' strategy, following what CEO Ilham Kadri described as "a comprehensive strategic review of our entire portfolio". The acronym comes from aims specific to the company's three realigned segments and the Solvay One operating model.
Subscribe to Ilham Kadri

 

 

 

AMRI banner advert